Defining Alzheimer’s disease: stipulations and the ethics of diagnostic change

Recent revisions of Alzheimer’s Disease (AD) definitions by two leading research groups—the Alzheimer’s Association and the International Working Group—reflect divergent approaches: the former promotes a strictly biological definition, while the latter promotes a clinicalbiological construct. We contend that this emerging controversy is not merely semantic, but scientifically, clinically, and politically significant. Drawing on philosophical tools and situating the current debate within a broader historical context from the reconceptualization of AD in the 1970s onwards, we explore how definitions can serve as transformative instruments, acting as strategic bets that reshape scientific fields and clinical practices. Ultimately, we draw from the AD case study to argue for a critical reflection on the risks and promises of such definitional acts. We also propose a renewed attention to the 'ethics of stipulating' in the field of contemporary biomedical sciences.

Authors

Institutions

Publication Details

Journal
Journal of Neurology Neurosurgery & Psychiatry
Published
2026-02-17
DOI
https://doi.org/10.1136/jnnp-2025-337832
Primary Topic
Mental Health and Psychiatry
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Defining Alzheimer’s disease: stipulations and the ethics of diagnostic change

Robin Michalon, Lara Keuck, Vincent V Planche, Maël Lemoine
Journal of Neurology Neurosurgery & Psychiatry
Mental Health and Psychiatry
article

Defining Alzheimer’s disease: stipulations and the ethics of diagnostic change

Robin Michalon, Lara Keuck, Vincent V Planche, Maël Lemoine
article en

Abstract

Recent revisions of Alzheimer’s Disease (AD) definitions by two leading research groups—the Alzheimer’s Association and the International Working Group—reflect divergent approaches: the former promotes a strictly biological definition, while the latter promotes a clinicalbiological construct. We contend that this emerging controversy is not merely semantic, but scientifically, clinically, and politically significant. Drawing on philosophical tools and situating the current debate within a broader historical context from the reconceptualization of AD in the 1970s onwards, we explore how definitions can serve as transformative instruments, acting as strategic bets that reshape scientific fields and clinical practices. Ultimately, we draw from the AD case study to argue for a critical reflection on the risks and promises of such definitional acts. We also propose a renewed attention to the 'ethics of stipulating' in the field of contemporary biomedical sciences.

Journal of Neurology Neurosurgery & Psychiatry
Centre National de la Recherche Scientifique (FR), Université de Bordeaux (FR), Inserm (FR), Bielefeld University (DE), Hochschule Bielefeld (DE), Sorbonne Université (FR), Institut des Maladies Neurodégénératives (FR), Assistance Publique – Hôpitaux de Paris (FR), Centre de recherche en Epidémiologie et Santé des Populations (FR), Immunology from Concept and Experiments to Translation (FR), Centre Alexandre Koyré (FR), Laboratoire d'études sur les monothéismes (FR), Pitié-Salpêtrière Hospital (FR), Institut du Cerveau (FR)
Eli Lilly and Company, Biogen, Biogen Idec, Bpifrance, Eisai, Novo Nordisk, Servier, FONDATION ALZHEIMER, UCB Pharma
Openalex Percentile: Top 53%
Mental Health and Psychiatry
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.